# Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

> **NCT00004939** · PHASE3 · COMPLETED · sponsor: **National Center for Research Resources (NCRR)** · enrollment: 34 (—)

## Conditions studied

- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

## Interventions

- **DRUG:** ,4-diaminopyridine

## Key facts

- **NCT ID:** NCT00004939
- **Lead sponsor:** National Center for Research Resources (NCRR)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08
- **Primary completion:** —
- **Final completion:** 1996-08
- **Target enrollment:** 34 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004939, "Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*